Phase I trial code: RD 787.36057 (MTX325-101)
| ISRCTN | ISRCTN20898392 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN20898392 |
| IRAS number | 1008552 |
| Secondary identifying numbers | MTX325-101, IRAS 1008552 |
- Submission date
- 05/03/2024
- Registration date
- 06/03/2024
- Last edited
- 06/03/2024
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Not Applicable
Plain English Summary
The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
Contact information
Scientific
Mission Therapeutics Ltd., The Glenn Berge Building, Babraham Research Campus
Cambridge
CB22 3FH
United Kingdom
| Phone | +44 (0) 1223 867926 |
|---|---|
| snurbhai@missiontherapeutics.com |
Public
Mission Therapeutics Ltd., The Glenn Berge Building, Babraham Research Campus
Cambridge
CB22 3FH
United Kingdom
| Phone | +44 (0) 7462 135809 |
|---|---|
| njones@missiontherapeutics.com |
Principal Investigator
Simbec-Orion Clinical Pharmacology, Merthyr Tydfil Industrial Park, Cardiff Road
Merthyr Tydfil
CF48 4DR
United Kingdom
| Phone | +44 (0)1443694313 |
|---|---|
| annelize.koch@simbecorion.com |
Study information
| Study design | A five-part first-in-human trial in up to 158 healthy participants and patients with mild to moderate Parkinson’s Disease |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Pharmaceutical testing facility |
| Study type | Safety |
| Participant information sheet | Not available in web format, please use contact details to request a participant information sheet. |
| Scientific title | Phase I trial code: RD 787.36057 (MTX325-101) |
| Study hypothesis | The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Ethics approval(s) |
1. Approved 21/11/2023, Wales Research Ethics Committee 2, Health and Care Research Wales (Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922 941119; Wales.REC2@wales.nhs.uk), ref: 23/WA/0258 2. Approved 30/11/2023, MHRA (MHRA, 10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom; +44 (0) 20 3080 6000; info@mhra.gov.uk), ref: CTA 56125/0002/001-0001 |
| Condition | The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Intervention | The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Intervention type | Drug |
| Pharmaceutical study type(s) | Pharmacokinetic, Pharmacogenetic |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Primary outcome measure | The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Secondary outcome measures | The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Overall study start date | 09/08/2023 |
| Overall study end date | 09/05/2026 |
Eligibility
| Participant type(s) | Healthy volunteer, Patient |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 75 Years |
| Sex | Both |
| Target number of participants | 158 |
| Participant inclusion criteria | The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Participant exclusion criteria | The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended. |
| Recruitment start date | 06/02/2024 |
| Recruitment end date | 14/11/2025 |
Locations
Countries of recruitment
- United Kingdom
- Wales
Study participating centre
Merthyr Tydfil Industrial Park
Pentrebach
Merthyr Tydfil
Mid Glamorgan
CF48 4DR
United Kingdom
Sponsor information
Industry
Mission Therapeutics Ltd., The Glenn Berge Building, Babraham Research Campus
Cambridge
CB22 3FH
England
United Kingdom
| Phone | None provided |
|---|---|
| info@missiontherapeutics.com | |
| Website | https://missiontherapeutics.com/ |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 31/12/2026 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not expected to be made available |
| Publication and dissemination plan | Full trial details will be published up to 30 months after the end of the trial. Publication of some trial details is deferred because of the high commercial sensitivity of this phase I study and the negligible benefit to the public of phase I information. Results will be posted on or after the date of publication of full trial details. |
| IPD sharing plan | The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials. |
Editorial Notes
05/03/2024: Study's existence confirmed by the Wales Research Ethics Committee 2, Health and Care Research Wales.
